CD63 and GLUT-1 Overexpression Could Predict a Poor Clinical Outcome in GIST: A Study of 54 Cases with Follow-Up

作者: Piotr Lewitowicz , Jarosław Matykiewicz , Dorota Koziel , Magdalena Chrapek , Agata Horecka-Lewitowicz

DOI: 10.1155/2016/6478374

关键词:

摘要: Background and Goals. In light of current knowledge, it seems that alternations underlying GISTs are well explained, although all is enhanced by various aspects on a daily basis. More recently, attention has been pointed towards exosomes as important particles able to modify healthy also diseased tissues including cancer. The goal the present study was an analysis CD9, CD63, GLUT-1 marker hypoxia status within 54 cases GIST evaluation their predictive value. Methods. patients suffering from were enrolled into study, predominantly in gastric location. All operated had no Imatinib other chemotherapies up day operation. Expression targeted proteins performed immunohistochemistry and, after that, results with tabulated clinical data compared Kaplan-Meier method multivariate Cox proportional hazard model statistical analysis. Results. Our presented marked dependence worsening outcome high expression CD63 (p = 0.008) 0.014). We noted strict correlation 0.03), which could confirm thesis about contribution intratumoural status. collected material did not CD9 contribution. Conclusions. As here, have prognostic value cases. studies this scope can be used future additional factor.

参考文章(31)
Yoko Murayama, Kenji Oritani, Shusaku Tsutsui, Novel CD9-targeted therapies in gastric cancer World Journal of Gastroenterology. ,vol. 21, pp. 3206- 3213 ,(2015) , 10.3748/WJG.V21.I11.3206
Jian Huan, Wenjiong Sheng, Jianping Cao, Jing Xu, Jiang Ji, Shuyu Zhang, Wei Zhu, Liyuan Zhang, Ye Tian, Yi Gao, Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma International Journal of Clinical and Experimental Pathology. ,vol. 8, pp. 3054- 3061 ,(2015)
Markku Miettinen, Jerzy Lasota, Histopathology of gastrointestinal stromal tumor. Journal of Surgical Oncology. ,vol. 104, pp. 865- 873 ,(2011) , 10.1002/JSO.21945
Muhammad Nawaz, Farah Fatima, Krishna C. Vallabhaneni, Patrice Penfornis, Hadi Valadi, Karin Ekström, Sharad Kholia, Jason D. Whitt, Joseph D. Fernandes, Radhika Pochampally, Jeremy A. Squire, Giovanni Camussi, Extracellular Vesicles: Evolving Factors in Stem Cell Biology Stem Cells International. ,vol. 2016, pp. 1073140- 1073140 ,(2016) , 10.1155/2016/1073140
MAOCHUN TANG, GUOJIAN YIN, FENG WANG, HUA LIU, SHU ZHOU, JIANBO NI, CONGYING CHEN, YINGQUN ZHOU, YAN ZHAO, Downregulation of CD9 promotes pancreatic cancer growth and metastasis through upregulation of epidermal growth factor on the cell surface Oncology Reports. ,vol. 34, pp. 350- 358 ,(2015) , 10.3892/OR.2015.3960
Hyeong Ju Kwon, Sun Young Min, Min Jee Park, Cheol Lee, Jeong Hwan Park, Ji Youn Chae, Kyung Chul Moon, Expression of CD9 and CD82 in clear cell renal cell carcinoma and its clinical significance. Pathology Research and Practice. ,vol. 210, pp. 285- 290 ,(2014) , 10.1016/J.PRP.2014.01.004
Piotr Rutkowski, Zbigniew I. Nowecki, Wanda Michej, Maria Dębiec-Rychter, Agnieszka Woźniak, Janusz Limon, Janusz Siedlecki, Urszula Grzesiakowska, Michał Kąkol, Czesław Osuch, Marcin Polkowski, Stanisław Głuszek, Zbigniew Żurawski, Włodzimierz Ruka, Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor Annals of Surgical Oncology. ,vol. 14, pp. 2018- 2027 ,(2007) , 10.1245/S10434-007-9377-9
Mrinal M. Gounder, Robert G. Maki, Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor Cancer Chemotherapy and Pharmacology. ,vol. 67, pp. 25- 43 ,(2011) , 10.1007/S00280-010-1526-3
Naoyuki Anzai, Younghee Lee, Byung-S. Youn, Seiji Fukuda, Young-June Kim, Charlie Mantel, Makoto Akashi, Hal E. Broxmeyer, C-kit associated with the transmembrane 4 superfamily proteins constitutes a functionally distinct subunit in human hematopoietic progenitors. Blood. ,vol. 99, pp. 4413- 4421 ,(2002) , 10.1182/BLOOD.V99.12.4413